Cevian Capital Raises Smith & Nephew Stake to 13.06% After Crossing Major Shareholding Threshold

Cevian Capital's Voting Rights in Smith & Nephew Now Stand at 13.06%

The TR-1 notification, filed on 25 June 2026 and completed in Jersey, confirms that Cevian Capital II GP Limited — the general partner of the Cevian Capital II fund complex — has increased its aggregate voting rights in Smith & Nephew PLC to 13.056468%. This equates to 110,517,469 voting rights in the FTSE 100 healthcare company, calculated as of the threshold-crossing date of 23 June 2026. The filing represents the latest in a series of disclosures that have established Cevian as one of Smith & Nephew's most significant shareholders.

The previous notification on record placed Cevian's holding at 12.235936%, meaning the move to 13.056468% represents an increase of approximately 0.82 percentage points. While this may appear incremental, in the context of a large-cap listed company such as Smith & Nephew, even a fractional increase of this magnitude represents the acquisition of millions of additional voting rights and signals a deliberate and continued accumulation of the position. The announcement states that no financial instruments such as Options, contracts for difference, or other derivative instruments form part of this holding — all exposure is through ordinary shares carrying full voting rights.

How the Shares Are Held: Aurora Nominees and UBS AG's Role as Custodian

The ownership structure disclosed in the filing involves multiple layers of nominee and custodian arrangements, which is standard practice for large institutional investors operating across jurisdictions. According to the notification, the legal owner of the Smith & Nephew shares is Aurora Nominees Limited, a company registered in London, United Kingdom, which acts in a nominee capacity. Aurora Nominees holds the shares on behalf of UBS AG, which in turn acts as custodian for the underlying beneficial owner — namely the Cevian Capital funds.

This arrangement means that while Aurora Nominees Limited appears as the registered shareholder in Smith & Nephew's share register, the economic and voting interest rests ultimately with Cevian Capital II GP Limited as general partner, acting on behalf of its limited Partnership structures. The notification is clear that all 110,517,469 voting rights are classified as indirect voting rights under DTR5.2.1, with zero direct voting rights attributed to Cevian itself. This is a common and legally straightforward structure for activist and institutional investors managing large positions through prime brokerage and global custody networks.

Breakdown of Cevian's Smith & Nephew Position Across Two Fund Vehicles

The chain of controlled undertakings section of the TR-1 filing provides a granular breakdown of how Cevian Capital II GP Limited's total 13.056468% stake is distributed across two separate fund vehicles. The larger portion — 11.868271% of voting rights — is held through Cevian Capital II Master Fund L.P., the main investment vehicle. A further 1.188196% is held through Cevian Capital II Co-Investment – Series P L.P., a co-investment structure that appears to be a dedicated series within the broader Cevian Capital II co-investment programme.

Both of these limited partnerships share the same general partner: Cevian Capital II G.P. Limited, which is registered in St Helier, Jersey. This structure is consistent with the way many European activist and long-only Equity funds organise their investment vehicles, allowing co-investors or specific mandates to participate alongside the main fund. The combined position across both vehicles totals the 13.056468% figure cited in the headline position. There are no financial instruments of any kind — neither DTR5.3.1R(1)(a) nor DTR5.3.1R(1)(b) instruments — disclosed in sections 8B1 or 8B2 of the filing.

What the DTR Threshold Notification Rules Mean for Smith & Nephew Investors

Under the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules, any investor acquiring or disposing of voting rights in a UK-listed company must notify both the company and the FCA when their holding crosses certain percentage thresholds — most commonly at 3%, 5%, 10%, 15%, and thereafter at each whole percentage point above 15%. The obligation to notify arises as soon as the threshold is crossed and must be completed within two trading days. In this case, the threshold was crossed on 23 June 2026 and the notification was submitted on 25 June 2026, which is consistent with this two-day requirement.

The crossing of the 13% level — while not itself a statutory threshold under DTR — is nonetheless a significant marker because it surpasses 10% and edges meaningfully closer to the 15% level at which a further notification would be required. For shareholders in Smith & Nephew, the disclosure confirms that Cevian has continued its accumulation of shares and now holds a voting stake large enough to exert considerable influence at general meetings, particularly in the context of resolutions requiring either a simple majority or, in some cases, a 75% supermajority. Investors may be watching to see whether Cevian's increased stake is accompanied by any updated public communication regarding the firm's intentions or agenda at the company.

Cevian Capital's Profile as a European Activist Investor

Cevian Capital is widely regarded as one of Europe's most prominent and disciplined activist investment managers. Founded in Sweden and operating with offices across Europe, the firm is known for taking concentrated, long-term positions in listed companies it believes are undervalued or operationally underperforming, and for engaging constructively — though at times persistently — with boards and management teams to drive improvements in strategy, capital allocation, and operational efficiency. The firm typically focuses on large-cap European companies with identifiable levers for value creation.

Cevian's continued accumulation of Smith & Nephew shares to above 13% indicates a high degree of conviction in the investment thesis. The disclosure suggests that Cevian views the current share price as offering attractive value relative to the company's underlying potential — though no formal statement of intentions has been made public as part of this TR-1 filing. The announcement does not contain any commentary from Cevian regarding its views on Smith & Nephew's strategy, management, or future direction, and the company has made no public statement in response to the notification at the time of writing.

Smith & Nephew PLC: Background on the FTSE 100 Medical Technology Group

Smith & Nephew PLC is a UK-headquartered global medical technology company with operations spanning orthopaedics, advanced wound management, and sports medicine and ENT (ear, nose, and throat) products. The company is listed on the London Stock Exchange as a constituent of the FTSE 100 Index and carries the ticker symbol SN. Its shares are identified by ISIN GB0009223206. With a history stretching back more than 160 years, Smith & Nephew serves patients, healthcare professionals, and health systems in more than 100 countries.

In recent years, Smith & Nephew has faced a variety of operational and strategic challenges, including Supply chain pressures, Margin headwinds, and questions around the pace of recovery in key surgical procedure volumes following the COVID-19 Pandemic. The company has undergone management changes and launched strategic initiatives aimed at restoring Revenue growth and improving profitability. It is against this backdrop that Cevian's continuing accumulation of the stock — now to above 13% — is likely to attract attention from the broader investment community, including fellow institutional shareholders and Sell-Side analysts covering the company.

Comparison with Cevian's Previously Notified Smith & Nephew Position

The previous TR-1 notification on record placed Cevian's total holding at 12.235936% of voting rights in Smith & Nephew. The latest filing, reflecting the position as of 23 June 2026, shows a new total of 13.056468% — an increase of approximately 0.820532 percentage points. In absolute terms, this suggests that Cevian has acquired a meaningful additional number of shares since its last notification, though the exact number of shares purchased in this latest Tranche is not separately identified in the announcement beyond the total figure of 110,517,469 voting rights now held.

The steady, incremental nature of this accumulation — moving from below 12.24% to above 13.05% — is consistent with the patient, deliberate approach that Cevian is known for in building its positions in target companies. The fact that the position has grown across multiple notification events suggests an ongoing and considered investment programme rather than a one-off block purchase. Investors and market observers may note that Cevian's trajectory, if continued, would bring the firm closer to the 15% threshold at which a further regulatory notification would be required.

Implications for Smith & Nephew's Shareholder Register and Corporate Governance

With 13.056468% of Smith & Nephew's voting rights now consolidated under a single activist investor, the dynamics of the company's shareholder base take on added significance from a corporate governance perspective. A holding of this scale gives Cevian considerable weight at annual general meetings and extraordinary general meetings alike. While a 13% stake is not sufficient to block a special resolution on its own — which typically requires 25% of votes cast against — it is more than sufficient to make a material impact on the outcome of ordinary resolutions and to signal publicly meaningful opposition to board proposals if Cevian chose to do so.

The concentration of such a large block in the hands of a single active manager also has implications for Smith & Nephew's board in terms of engagement. UK corporate governance norms, as reflected in the UK Corporate Governance Code and associated guidance from bodies such as the Investment Association, encourage boards to engage proactively with major shareholders. A 13% shareholder of Cevian's profile and reputation would typically expect — and receive — regular, substantive dialogue with the chair, chief executive, and chief financial officer. The announcement does not indicate whether any such engagement is ongoing, but the scale of the position makes it a near-certainty that the relationship between Cevian and Smith & Nephew's board will be a matter of continued scrutiny for investors.

Immediate Market Reaction and Investor Considerations Going Forward

The immediate share price impact of this announcement was not clear from available public information at the time of writing. Major shareholding notifications of this nature do not always produce an immediate or dramatic market reaction, particularly when the investor in question is already a well-known and previously disclosed major shareholder. However, the confirmation of a further increase in Cevian's position may be read by some Market Participants as a positive signal regarding the investment case for Smith & Nephew shares, given Cevian's track record of investing in companies where it sees a credible path to value creation.

Investors in Smith & Nephew may wish to monitor several developments in the weeks and months ahead. These include any public statement from Cevian Capital regarding its intentions or views on the company's strategy; any response or commentary from Smith & Nephew's board or Investor relations function; whether Cevian continues to accumulate shares towards the 15% notification threshold; and the broader context of Smith & Nephew's own financial and operational performance. Analysts and fund managers tracking the stock will also be aware that a further TR-1 notification would be triggered if Cevian's stake were to cross 14% or 15%, which would represent yet another escalation of the firm's already substantial commitment to the investment.